Disseminated Kaposi's sarcoma after heart transplantation: association with Kaposi's sarcoma-associated herpesvirus.
BACKGROUND
Kaposi's sarcoma is an endothelial tumor rarely diagnosed after heart transplantation. We report on a patient originally from Africa in whom Kaposi's sarcoma developed in association with Kaposi's sarcoma-associated herpesvirus.


METHODS
A man from Ghana had constitutional symptoms associated with multiple pulmonary nodules that developed 3 months after heart transplantation. Kaposi's sarcoma was diagnosed by thorascopic biopsy. Treatment consisted of reducing immunosuppression therapy and adding famciclovir treatment. Symptoms resolved within 1 month after treatment, and no disease progression was observed for 5 months. The patient died suddenly 8 months after heart transplantation; autopsy revealed occlusion of the left anterior descending coronary artery and grade 3A rejection. Extensive Kaposi's sarcoma was observed in the lungs and gastrointestinal tract at autopsy.


RESULTS
Pathologic analysis of the tumor demonstrated features consistent with Kaposi's sarcoma. Polymerase chain reaction and in situ hybridization demonstrated the presence of Kaposi's sarcoma-associated herpesvirus.


CONCLUSIONS
Kaposi's sarcoma rarely is diagnosed after transplantation. Patients infected with Kaposi's sarcoma-associated herpesvirus may be at increased risk. Screening for Kaposi's sarcoma-associated herpesvirus may be indicated in patients at risk. The role of antiviral medications and immunization in the treatment and prevention of the disorder is unknown.
The Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA.
R
R
Fonseca
T E
TE
Witzig
L J
LJ
Olson
B S
BS
Edwards
A
A
Khoor
R C
RC
Walker
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D000077595:Famciclovir; D016027:Heart Transplantation; D019288:Herpesvirus 8, Human / Q000302:isolation & purification*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000821:virology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000821:virology*; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000821:virology*
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D015075:2-Aminopurine; D000077595:Famciclovir